Have a feature idea you'd love to see implemented? Let us know!

IONS Ionis Pharmaceuticals Inc

Price (delayed)

$38.77

Market cap

$5.67B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.52

Enterprise value

$6.82B

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and ...

Highlights
The gross profit is up by 29% year-on-year and by 4.6% since the previous quarter
IONS's revenue is up by 29% YoY and by 4.7% QoQ
The net income has declined by 18% year-on-year but it has increased by 4.9% since the previous quarter
Ionis Pharmaceuticals's EPS has decreased by 16% YoY but it has increased by 6% QoQ
The company's equity fell by 38% YoY and by 11% QoQ
IONS's quick ratio is down by 18% year-on-year

Key stats

What are the main financial stats of IONS
Market
Shares outstanding
146.21M
Market cap
$5.67B
Enterprise value
$6.82B
Valuations
Price to book (P/B)
21.46
Price to sales (P/S)
6.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.38
Earnings
Revenue
$813.46M
EBIT
-$263.22M
EBITDA
-$240.79M
Free cash flow
-$358M
Per share
EPS
-$2.52
Free cash flow per share
-$2.45
Book value per share
$1.81
Revenue per share
$5.57
TBVPS
$18.44
Balance sheet
Total assets
$2.69B
Total liabilities
$2.43B
Debt
$1.44B
Equity
$263.7M
Working capital
$2.02B
Liquidity
Debt to equity
5.47
Current ratio
7.61
Quick ratio
6.88
Net debt/EBITDA
-4.77
Margins
EBITDA margin
-29.6%
Gross margin
98.6%
Net margin
-45%
Operating margin
-44.9%
Efficiency
Return on assets
-12.9%
Return on equity
-115.9%
Return on invested capital
-7.4%
Return on capital employed
-11%
Return on sales
-32.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IONS stock price

How has the Ionis Pharmaceuticals stock price performed over time
Intraday
0.91%
1 week
0.73%
1 month
-5.44%
1 year
-16.23%
YTD
-23.36%
QTD
-3.22%

Financial performance

How have Ionis Pharmaceuticals's revenue and profit performed over time
Revenue
$813.46M
Gross profit
$801.89M
Operating income
-$364.99M
Net income
-$365.74M
Gross margin
98.6%
Net margin
-45%
The operating margin is up by 40% year-on-year and by 10% since the previous quarter
The gross profit is up by 29% year-on-year and by 4.6% since the previous quarter
IONS's revenue is up by 29% YoY and by 4.7% QoQ
IONS's operating income is up by 23% year-on-year and by 6% since the previous quarter

Growth

What is Ionis Pharmaceuticals's growth rate over time

Valuation

What is Ionis Pharmaceuticals stock price valuation
P/E
N/A
P/B
21.46
P/S
6.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.38
Ionis Pharmaceuticals's EPS has decreased by 16% YoY but it has increased by 6% QoQ
The stock's price to book (P/B) is 92% more than its 5-year quarterly average of 11.2
The company's equity fell by 38% YoY and by 11% QoQ
IONS's revenue is up by 29% YoY and by 4.7% QoQ
The P/S is 24% less than the last 4 quarters average of 9.1 and 14% less than the 5-year quarterly average of 8.1

Efficiency

How efficient is Ionis Pharmaceuticals business performance
IONS's return on equity has dropped by 95% year-on-year and by 7% since the previous quarter
Ionis Pharmaceuticals's return on sales has increased by 15% YoY and by 9% QoQ
IONS's return on assets is down by 13% year-on-year but it is up by 2.3% since the previous quarter
Ionis Pharmaceuticals's ROIC has decreased by 6% YoY but it has increased by 3.9% from the previous quarter

Dividends

What is IONS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IONS.

Financial health

How did Ionis Pharmaceuticals financials performed over time
The total assets is 11% greater than the total liabilities
IONS's quick ratio is down by 18% year-on-year
The current ratio has declined by 16% year-on-year but it rose by 3.3% since the previous quarter
Ionis Pharmaceuticals's debt to equity has soared by 57% YoY and by 12% from the previous quarter
The company's equity fell by 38% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.